ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01672 ASCLETIS-B

Market Closed 12-12 16:08:09

14.520

-0.480

-3.20%

High15.210	Low14.340	Vol5.16M
Open15.200	D1 Closing15.000	Amplitude5.80%
Mkt Cap14.40B	Tradable Cap14.40B	Total Shares992.00M
T/O75.74M	T/O Rate0.52%	Tradable Shares992.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"ASCLETIS-B","latestPrice":14.52,"timestamp":1765526889004,"preClose":15,"halted":0,"volume":5162546,"delay":0,"floatShares":992000000,"shares":992000000,"eps":-0.3314595646787849,"marketStatus":"Market Closed","change":-0.48,"latestTime":"12-12 16:08:09","open":15.2,"high":15.21,"low":14.34,"amount":75735311,"amplitude":0.058,"askPrice":14.52,"askSize":1000,"bidPrice":14.5,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.2926684102651893,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":7,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":15,"openAndCloseTimeList":[[1765503000000,1765512000000],[1765515600000,1765526400000]],"volumeRatio":0.40263323297181375,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672","defaultTab":"news","newsList":[{"id":"2590557700","title":"Ascletis Pharma Repurchases 300,000 Shares at HK$14.8 Each, Files Disclosure with HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2590557700","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590557700?lang=en_us&edition=fundamental","pubTime":"2025-12-12 18:20","pubTimestamp":1765534803,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has filed a next day disclosure return with the Hong Kong Stock Exchange, reporting the repurchase of a total of 300,000 shares. The shares were repurchased at prices ranging from HKD 14.38 to HKD 14.80, with an aggregate price paid of HKD 4,373,830.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDLpC8G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","01672","BK1515"],"gpt_icon":0},{"id":"2590459300","title":"Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (Asc40), a First-in-Class Fasn Inhibitor for Acne Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2590459300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590459300?lang=en_us&edition=fundamental","pubTime":"2025-12-10 17:15","pubTimestamp":1765358100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA1X77P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","BK1574","01672"],"gpt_icon":0},{"id":"1127214575","title":"ASCLETIS-B (01672): First-in-Class FASN Inhibitor Denifanstat (ASC40) NDA for Acne Treatment Accepted by China NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1127214575","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127214575?lang=en_us&edition=fundamental","pubTime":"2025-12-10 17:10","pubTimestamp":1765357824,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) announced that the New Drug Application (NDA) for denifanstat (ASC40), a first-in-class, once-daily oral small-molecule fatty acid synthase (FASN) inhibitor targeting...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01477","BK1191","01672","BK1515","BK1161"],"gpt_icon":0},{"id":"2590030055","title":"China NMPA Accepts New Drug Application for Ascletis Pharma's Denifanstat for Acne Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2590030055","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590030055?lang=en_us&edition=fundamental","pubTime":"2025-12-10 17:02","pubTimestamp":1765357321,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. announced that the China National Medical Products Administration  has accepted its New Drug Application  for denifanstat , a first-in-class, once-daily oral small molecule fatty acid synthase  inhibitor, for the treatment of moderate-to-severe acne vulgaris. The NDA acceptance follows successful Phase III clinical trial results in which denifanstat met all primary and key secondary efficacy endpoints compared to placebo. The company recently completed a pre-NDA consultation with positive feedback from the NMPA. No grant or funding involving multiple organizations is mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL83ydPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","BK1161","01672"],"gpt_icon":0},{"id":"2590300371","title":"Ascletis Pharma Inc - Nmpa Acceptance of Nda for Denifanstat","url":"https://stock-news.laohu8.com/highlight/detail?id=2590300371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590300371?lang=en_us&edition=fundamental","pubTime":"2025-12-10 17:01","pubTimestamp":1765357301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XF14I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","01672","BK1515"],"gpt_icon":0},{"id":"2590971183","title":"Shares of Chinese Drugmaker Ascletis Rise on Weight-Loss Drug Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2590971183","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590971183?lang=en_us&edition=fundamental","pubTime":"2025-12-09 14:24","pubTimestamp":1765261440,"startTime":"0","endTime":"0","summary":"Shares of Ascletis Pharma surged Tuesday morning after the Chinese drugmaker said its weight-loss drug performed well in a study.The stock rose over 24% in Hong Kong to touch a four-month high before pulling back slightly. It is on track for its strongest day of gains since May, outperforming both the Hang Seng Index and the benchmark for biotech stocks, both of which were down more 1%.Ascletis's rally was sparked by positive results of a U.S. study of ASC30 tablets for obese and overweight patients.ASC30--Ascletis's contender in the GLP-1 class of weight-loss drugs like Ozempic and Wegovy--showed \"statistically significant and clinically meaningful\" weight loss in the phase II study, the China-based company said in a filing.The drug met key endpoints--clinical trial outcomes that help determine efficacy and safety--including reducing cholesterol and blood pressure, Ascletis said Monday.The firm plans to submit the data to the U.S. Food and Drug Administration as it looks to start phas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Shares of Chinese Drugmaker Ascletis Rise on Weight-Loss Drug Results","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01672","BK1515","BK1574"],"gpt_icon":0},{"id":"1140883678","title":"Citi: Ascletis-B's ASC30 Phase IIa Data Further Demonstrates Best-in-Class Potential, Reiterates \"Buy/High Risk\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1140883678","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140883678?lang=en_us&edition=fundamental","pubTime":"2025-12-09 14:20","pubTimestamp":1765261226,"startTime":"0","endTime":"0","summary":"Citi released a research report stating that it expects a positive reaction in the share price of Ascletis-B (01672), reiterating a \"Buy/High Risk\" rating with a target price of HK$32. Citi believes...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","LU1791807156.HKD","01477","BK1515","LU2360032135.SGD","IE00BSNM7G36.USD","01672","LU0098860793.USD","LU0310800965.SGD","LU1201861249.SGD","LU1244550221.USD","LU1668664300.SGD","C","LU1162221912.USD","LU0130517989.USD","LU0130102774.USD","BK4588","LU0320765646.SGD","BK1191","BK4207","LU0477156953.USD","LU2125154778.USD","LU0128525689.USD","BK1161","LU0162691827.USD","BK4534","LU0106831901.USD","LU0052756011.USD","BK4559","LU1366192091.USD","LU2462157665.USD","LU1244550494.USD","LU1244550577.SGD","LU2125154935.USD","BK4585","LU1267930227.SGD","LU0648001328.SGD","LU2417539215.USD","LU0072461881.USD","LU0980610538.SGD","LU2456880835.USD","BK1574","LU0170899867.USD","BK4566","LU2236285917.USD"],"gpt_icon":0},{"id":"1151245949","title":"Hong Kong Stocks Narrowly Fluctuate; ASCLETIS-B Surges Over 23% on Positive News","url":"https://stock-news.laohu8.com/highlight/detail?id=1151245949","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151245949?lang=en_us&edition=fundamental","pubTime":"2025-12-09 11:00","pubTimestamp":1765249240,"startTime":"0","endTime":"0","summary":"Hong Kong stocks opened slightly higher and traded within a narrow range in early trading on December 9. As of the latest update, the Hang Seng Index stood at 25,747.45 points, down 17.31 points or...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"eb673bcce88aebafcbc37fb491eb2df2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1161","01477","BK1574","BK1515","01672"],"gpt_icon":0},{"id":"1189609357","title":"HK Movers | Biomedical Stocks Jump With Ascletis Pharma up 21%, Sirnaomics up 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189609357","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189609357?lang=en_us&edition=fundamental","pubTime":"2025-12-09 10:07","pubTimestamp":1765246076,"startTime":"0","endTime":"0","summary":"Biomedical stocks jumped in Hong Kong. Ascletis Pharma rose 21%; Sirnaomics rose 11%; Joinn Laboratories rose 10%; WuXi XDC rose 5%; Pharmaron and WuXi Biologics rose 4%; WuXi AppTec rose 3%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"eb673bcce88aebafcbc37fb491eb2df2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","02257","03759","06127","01672","02268","02359"],"gpt_icon":0},{"id":"1111095216","title":"HK Movers | Ascletis Pharma Surges as ASC30 Shows Positive Top-Line Results in 13-Week Phase 2 Obesity Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1111095216","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111095216?lang=en_us&edition=fundamental","pubTime":"2025-12-09 09:37","pubTimestamp":1765244220,"startTime":"0","endTime":"0","summary":"Ascletis Pharma surged 23.3% in Hong Kong.Ascletis Pharma announced that its 13-week Phase II study (NCT07002905) evaluating the oral small-molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"gpt_icon":1},{"id":"2589903336","title":"Ascletis Pharma Inc - Asc30 Tablets Show Significant Dose-Dependent Weight Reductions","url":"https://stock-news.laohu8.com/highlight/detail?id=2589903336","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589903336?lang=en_us&edition=fundamental","pubTime":"2025-12-08 17:40","pubTimestamp":1765186817,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XC0LM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","BK1515","01672"],"gpt_icon":0},{"id":"2589369013","title":"Ascletis' Oral Small Molecule Glp-1, Asc30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% With Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase Ii Study in Participants With Obesity or Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2589369013","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589369013?lang=en_us&edition=fundamental","pubTime":"2025-12-08 17:40","pubTimestamp":1765186817,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XC0LM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01672","BK1574","BK1515"],"gpt_icon":0},{"id":"2589336188","title":"Ascletis Pharma Inc - No Hepatic Safety Signal Observed in Asc30 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2589336188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589336188?lang=en_us&edition=fundamental","pubTime":"2025-12-08 17:40","pubTimestamp":1765186817,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XC0LM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01672","BK1574","BK1515"],"gpt_icon":0},{"id":"1114216278","title":"ASCLETIS-B (01672): Positive Topline Results from 13-Week Phase II Study of ASC30 for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1114216278","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114216278?lang=en_us&edition=fundamental","pubTime":"2025-12-08 17:38","pubTimestamp":1765186708,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) announced positive topline results from its 13-week Phase II study (NCT07002905) evaluating the oral small-molecule GLP-1 receptor (GLP-1R) agonist ASC30 for obesity treatment....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","BK1574","01672","BK1191","01477"],"gpt_icon":0},{"id":"2589533651","title":"Ascletis Pharma Reports 7.7% Placebo-Adjusted Weight Loss With Oral GLP-1 Drug ASC30 in Phase II Obesity Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2589533651","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589533651?lang=en_us&edition=fundamental","pubTime":"2025-12-08 17:31","pubTimestamp":1765186261,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has announced positive topline results from a 13-week Phase II clinical study evaluating ASC30, an oral small molecule GLP-1 receptor agonist, for the treatment of obesity or overweight with at least one weight-related comorbidity. The study, conducted at multiple sites in the United States and involving 125 participants, investigated three dose levels of ASC30 oral tablets . All three doses met the primary endpoint compared to placebo, demonstrating a placebo-adjusted weight loss of 7.7% and improved gastrointestinal tolerability. The results have already been presented in the company's announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL9dXvlX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1515","01672"],"gpt_icon":0},{"id":"1109198656","title":"ASCLETIS-B (01672) Surges Over 4% as New Drug Denifanstat Tablet's Marketing Application Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1109198656","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109198656?lang=en_us&edition=fundamental","pubTime":"2025-12-08 13:47","pubTimestamp":1765172858,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) rose more than 4%, reaching HK$14.23 by the time of writing, with a trading volume of HK$26.83 million. On December 4, the CDE website showed that the marketing application for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1191","01672","BK1574","01477","BK1161"],"gpt_icon":0},{"id":"2589787638","title":"Is Ascletis Pharma (SEHK:1672) Quietly Reframing Its Obesity Strategy With ASC37’s Oral Triple Agonist?","url":"https://stock-news.laohu8.com/highlight/detail?id=2589787638","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589787638?lang=en_us&edition=fundamental","pubTime":"2025-12-07 09:25","pubTimestamp":1765070728,"startTime":"0","endTime":"0","summary":"In late November 2025, Ascletis Pharma announced it had selected ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist developed with its POTENT and AI-assisted technologies, as a clinical development candidate and outlined plans to file a US FDA Investigational New Drug application for obesity treatment in 2026.\nThe company highlighted that ASC37 showed much higher in vitro potency and substantially improved oral bioavailability versus existing incretin drugs in non-human primate studies,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/is-ascletis-pharma-sehk1672-quietly-reframing-its-obesity-st","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/is-ascletis-pharma-sehk1672-quietly-reframing-its-obesity-st","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1161","BK1515","01672"],"gpt_icon":0},{"id":"2589818826","title":"Assessing Ascletis Pharma (SEHK:1672) Valuation After New ASC37 Obesity Candidate Advances Toward FDA IND Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818826","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818826?lang=en_us&edition=fundamental","pubTime":"2025-12-05 15:12","pubTimestamp":1764918731,"startTime":"0","endTime":"0","summary":"Ascletis Pharma (SEHK:1672) just flagged a major pipeline milestone, selecting its in house, AI optimized ASC37 oral triple peptide agonist for clinical development in obesity, with an FDA IND filing targeted for 2026.\nSee our latest analysis for Ascletis Pharma.\nThat R&D breakthrough lands after a wild run in the stock, with a 1 month share price return of 42.97 percent and a massive 1 year total shareholder return of 663.58 percent, suggesting momentum is still very much alive.\nIf this kind...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/assessing-ascletis-pharma-sehk1672-valuation-after-new-asc37","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/assessing-ascletis-pharma-sehk1672-valuation-after-new-asc37","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01672","BK1161","IND","BK1515","BK1574"],"gpt_icon":0},{"id":"1188939374","title":"ASCLETIS-B (01672) Repurchases 1.62 Million Shares for HK$20.94 Million on December 4","url":"https://stock-news.laohu8.com/highlight/detail?id=1188939374","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188939374?lang=en_us&edition=fundamental","pubTime":"2025-12-04 17:42","pubTimestamp":1764841332,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) announced that on December 4, 2025, the company repurchased 1.62 million shares at a total cost of HK$20.94 million. The repurchase price ranged between HK$12.33 and HK$13.23 per share.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","01477","BK1161","01672","BK1191"],"gpt_icon":0},{"id":"2588008740","title":"Ascletis Pharma Files HKEX Disclosure on Repurchase of 1.62 Million Shares for HK$20.94 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2588008740","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588008740?lang=en_us&edition=fundamental","pubTime":"2025-12-04 17:36","pubTimestamp":1764840976,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has filed a next day disclosure return with the Hong Kong Stock Exchange, reporting the repurchase of 1,620,000 ordinary shares for a total aggregate price of HKD 20,938,940. The repurchased shares are intended for cancellation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL4VNCfy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01672","BK1161","BK1515"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":0.0637},{"period":"1month","weight":0.2872},{"period":"3month","weight":0.3034},{"period":"6month","weight":0.5381},{"period":"1year","weight":5.9808},{"period":"ytd","weight":3.8239}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.137639},{"month":2,"riseRate":0.714286,"avgChangeRate":0.094063},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.058802},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.059274},{"month":5,"riseRate":0.428571,"avgChangeRate":0.007612},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.024499},{"month":7,"riseRate":0.571429,"avgChangeRate":0.032162},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.037953},{"month":9,"riseRate":0.125,"avgChangeRate":-0.072967},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.11407}],"exchange":"SEHK","name":"ASCLETIS-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ASCLETIS-B(01672) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ASCLETIS-B,01672,ASCLETIS-B股票,ASCLETIS-B股票老虎,ASCLETIS-B股票老虎国际,ASCLETIS-B行情,ASCLETIS-B股票行情,ASCLETIS-B股价,ASCLETIS-B股市,ASCLETIS-B股票价格,ASCLETIS-B股票交易,ASCLETIS-B股票购买,ASCLETIS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ASCLETIS-B(01672) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}